131 related articles for article (PubMed ID: 8566090)
1. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice.
Wentworth PA; Vitiello A; Sidney J; Keogh E; Chesnut RW; Grey H; Sette A
Eur J Immunol; 1996 Jan; 26(1):97-101. PubMed ID: 8566090
[TBL] [Abstract][Full Text] [Related]
2. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
Shirai M; Arichi T; Nishioka M; Nomura T; Ikeda K; Kawanishi K; Engelhard VH; Feinstone SM; Berzofsky JA
J Immunol; 1995 Mar; 154(6):2733-42. PubMed ID: 7533182
[TBL] [Abstract][Full Text] [Related]
3. Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes.
Alexander J; Oseroff C; Sidney J; Wentworth P; Keogh E; Hermanson G; Chisari FV; Kubo RT; Grey HM; Sette A
J Immunol; 1997 Nov; 159(10):4753-61. PubMed ID: 9366399
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
5. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.
Lustgarten J; Theobald M; Labadie C; LaFace D; Peterson P; Disis ML; Cheever MA; Sherman LA
Hum Immunol; 1997 Feb; 52(2):109-18. PubMed ID: 9077559
[TBL] [Abstract][Full Text] [Related]
6. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
7. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.
Butterfield LH; Koh A; Meng W; Vollmer CM; Ribas A; Dissette V; Lee E; Glaspy JA; McBride WH; Economou JS
Cancer Res; 1999 Jul; 59(13):3134-42. PubMed ID: 10397256
[TBL] [Abstract][Full Text] [Related]
8. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance.
Vitiello A; Sette A; Yuan L; Farness P; Southwood S; Sidney J; Chesnut RW; Grey HM; Livingston B
Eur J Immunol; 1997 Mar; 27(3):671-8. PubMed ID: 9079808
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocyte recognition of HLA-A2 antigens in normal and HLA-Cw3-transgenic mice.
Hämmerling GJ; Hunt T; Dill O; Moreno J
Eur J Immunol; 1989 Apr; 19(4):599-604. PubMed ID: 2786469
[TBL] [Abstract][Full Text] [Related]
11. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
[TBL] [Abstract][Full Text] [Related]
12. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection.
Nayersina R; Fowler P; Guilhot S; Missale G; Cerny A; Schlicht HJ; Vitiello A; Chesnut R; Person JL; Redeker AG; Chisari FV
J Immunol; 1993 May; 150(10):4659-71. PubMed ID: 7683326
[TBL] [Abstract][Full Text] [Related]
13. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers.
Wizel B; Houghten R; Church P; Tine JA; Lanar DE; Gordon DM; Ballou WR; Sette A; Hoffman SL
J Immunol; 1995 Jul; 155(2):766-75. PubMed ID: 7541824
[TBL] [Abstract][Full Text] [Related]
14. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.
Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; Prieto J; Celis E; Borrás-Cuesta F
Clin Cancer Res; 2002 Jul; 8(7):2336-44. PubMed ID: 12114438
[TBL] [Abstract][Full Text] [Related]
15. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
[TBL] [Abstract][Full Text] [Related]
16. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
[TBL] [Abstract][Full Text] [Related]
17. Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein.
Engelhard VH; Lacy E; Ridge JP
J Immunol; 1991 Feb; 146(4):1226-32. PubMed ID: 1704033
[TBL] [Abstract][Full Text] [Related]
18. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD
J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer.
Xu DH; Zhou CH; Xia YP; Qiu ZY; Wu YZ; Jia ZC; Zhou W
Acta Pharmacol Sin; 2007 May; 28(5):695-702. PubMed ID: 17439726
[TBL] [Abstract][Full Text] [Related]
20. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
